Accelerate biotechnology

Meet the experts

Quality specialist is key in any biopharmaceutical development team

Meet the Expert: Margreet, QA specialist The ability to translate biopharmaceutical research into products is known to have a high failure rate. A staggering 75% of published pre-clinical data cannot be reproduced or validated to allow further product development1. I believe that the only way to prevent such disappointments both scientifically, as well as commercially,…


The E. coli platform for production of therapeutic antibody fragments

Meet the Expert: Pranav, Microbial Bioprocess Scientist E. coli has been used as a platform for the production of therapeutic proteins since the late 1970’s. The organism is a well-known and cost-effective biological production factory for which many genetic tools and scale up cultivation strategies are available. As a matter of fact, around 30% of…


The need to increase production yield of therapeutic proteins

Meet the Expert: Rizwan, Cell Line & Technology Scientist. Biopharmaceuticals are expensive due to the many years of research and development associated with the discovery, development, clinical testing, and market launch of these medicines. As an example; the Food and Drug Administration (FDA) approved a monoclonal antibody called ipilimumab (Yervoy; Bristol-Myers Squibb, New York, NY)…


Novel HPLC assays allow for better biopharmaceutical development

Meet the expert: Xia, Analytical Assay Scientist. HPLC has been widely used for decades in the analysis of small molecules and is gaining momentum as an important tool for analyzing biotechnology products. For instance, HPLC has been successfully introduced for the analysis of monoclonal antibody-based products and is more and more used for large particle…


How to scale your adherent cell culture

Meet the expert: Matthijs, Bioprocess Scientist. Cells derived from mammalian species and cultured under artificial laboratory conditions have been used to produce complex biological products. As such cells normally grow as a tissue, most available artificial mammalian cells are originally surface-dependent and therefore are called adherent cells. Adherent cells will only duplicate and produce a…


The future of the biotech outsourcing market

Meet the expert: Menzo Havenga, President & CEO. The current biotech outsourcing market for biopharmaceuticals encompasses about $5.5 billion annually with by far the biggest spending in early development. It is estimated that about two-thirds of that annual spending is currently outsourced with about 90% being spent by small and mid-size biotech companies. In contrast,…